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ABSTRACT
Objective: To evaluate the effect of using antihypertensive classes of drugs of the 
calcium channel antagonists and inhibitors of angiotensin-converting enzyme in plasma 
concentrations of hydrogen sulfide and nitric oxide in patients with hypertension. 
Methods: Cross-sectional study with quantitative approach conducted with hypertensive 
patients in use of antihypertensive classes of drugs: angiotensin-converting enzyme 
inhibitors or calcium channel antagonists. Results: It was found that the concentration 
of plasma nitric oxide was significantly higher in hypertensive patients that were in 
use of angiotensin-converting enzyme inhibitors (p<0.03) and the hydrogen sulphide 
concentration was significantly higher in hypertensive plasma in use of calcium channel 
antagonists (p<0.002). Conclusion: The findings suggest that these medications have 
as additional action mechanism the improvement of endothelial dysfunction by elevate 
plasma levels of vasodilatory substances.
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INTRODUCTION
The systemic arterial hypertension (SAH) is a common 
cardiovascular disease and the main risk factor for cerebro-
vascular accident (CVA) or heart diseases(1). In the United 
States of America, the prevalence rate of SAH are approxi-
mately 40% in adults over 20 years, being almost equal be-
tween men and women. Among adults with hypertension, 
80% know their condition, 71% use antihypertensive drugs 
and only 48% of those who are aware of his/her illness have 
controlled blood pressure(2).
Among the pathophysiological mechanisms of SAH, 
we include the role of the vascular endothelium. Endothe-
lial cells play a key role in the regulation of vascular tone 
through the synthesis and release of relaxation and con-
traction factors. Nitric oxide (NO) is considered the key 
molecule involved in cardiovascular homeostasis(3). A recent 
study has provided evidence to support the premise that the 
hydrogen sulphide (H2S) is an endothelium-derived relax-
ing factor(4). In general, it can be affirmed that the H2S is 
a vasodilator substance capable of inducing an antihyper-
tensive effect(5).
With regard to SAH treatment, in a meta-analysis of 
147 randomized studies, the authors found that in patients 
receiving treatment with antihypertensive medications there 
was a 22% reduction in coronary heart disease and a 41% 
reduction in CVA(6), what demonstrates its great impor-
tance in reducing cardiovascular morbidity and mortality.
Considering the mechanism of knowledge of antihyper-
tensive drugs’ action, as well as gaseous mediators and their 
physiological and pathophysiological processes, it is relevant 
to the training of nurses in various specialties, the present 
study aimed to compare plasma concentrations of gaseous 
mediators nitric oxide (NO) and hydrogen sulphide (H2S) 
and check if there are associations between these media-
tors in hypertensive patients treated with calcium channel 
antagonists (CCA) and angiotensin-converting enzyme 
inhibitors (ACE inhibitor).
METHOD
Cross-sectional study, with a quantitative approach, con-
ducted in a health unit located in a countryside city in the 
State of Sao Paulo, in the period from February to Novem-
ber 2013. We included patients with medical diagnosis of 
hypertension, antihypertensive monotherapy for more than 
five years, being the medication belonging to the classes of 
drugs: calcium channel antagonists or inhibitors of angio-
tensin-converting enzyme. The name of these patients were 
identified by a report in a software from the Pharmacy in 
the health unit, which generates patients’ reports according 
to drug class in use.
When they were attended at the Health Unit for a clini-
cal consultation, patients were asked to participate as subjects 
of research, moment when they received detailed orientation 
about the objectives and procedures to be performed.
The criteria adopted for exclusion were: age below 18 
years, patients with terminal stage disease, like neoplasms or 
Aids and patients who were receiving other antihypertensive 
classes of drug not belonging to the calcium channel antag-
onists or inhibitors of angiotensin-converting enzyme.
A total of 36 participants were selected according to the 
inclusion and exclusion criteria, of these, 16 used antihyper-
tensive drugs in the class of calcium channel antagonists 
and 20 used antihypertensive drugs in the class of angio-
tensin-converting enzyme inhibitors.
Initially the patients attended a nursing consultation, 
where they filled in a questionnaire containing general 
identification data (age, gender and skin color) and the 
names of the medications in use. The blood collection was 
scheduled and orientation was provided on the preparation 
for the procedure.
Venipuncture is a complex procedure, which requires 
knowledge and skill. The recommendations followed the 
standards of the Clinical and Laboratory Standards Insti-
tute (CLSI). The CLSI is an international, interdisciplinary, 
non-profit, recognized worldwide institute by promoting 
the development and use of voluntary standards and guide-
lines in the context of health care(7).
The blood sample collection for carrying out the labora-
tory tests was performed after the consent of the patients. 
We collected from each individual 10 ml of blood in tube 
containing 0.5 ml of heparin for determination of hydrogen 
sulfide and nitrate plasma levels after fasting for 12 hours.
Laboratory testing of these samples was divided in two 
steps, the first carried out by centrifuge lab accredited by 
the Municipal Health Secretariat – Unified Health System 
(SUS), and the second step was conducted in the laboratory 
of Physiology of Nursing School of Ribeirao Preto (USP).
First step – Laboratory accredited by the Municipal 
Health Secretariat – Unified Health System (SUS). Sam-
ples were centrifuged at the Laboratory accredited by the 
Municipal Health Secretariat, at 3000 rpm for 20 minutes, 
immediately after the collection has been made, for separa-
tion of the plasma, which was stored at -70°C. According 
to the Brazilian Society of Pathology(7), the time between 
collection and centrifugation of the blood should not exceed 
one hour. These samples were carried in coolers with ice and 
thermometer for the laboratory of Physiology of the School 
of Nursing of Ribeirao Preto (USP), in a period of an hour 
and a half, where we conducted the next step, the determi-
nation of hydrogen sulphide and nitrate levels.
Second step – Laboratory of Physiology of the School 
of Nursing of Ribeirao Preto (USP). Dosage of H2S-every 
sample of 200µl of plasma was added 20µl of L-cysteine 
10mM, 20 µl of pyridoxal 5-phosphatase and 30µl of PBS 
incubated for 2 hours at 37°C. Zinc acetate (1% 100µl) was 
then added followed by the addition of trichloroacetic acid 
(10% (w/v)/ 100 µl) to precipitate the protein and thus stop 
the reaction. After new centrifugation 50 µl of N-dimethyl 
sulfate-p-phenilenediamina 20 mM was added followed by 
50µl FeCl3 30 mM. A sample of the supernatant (50 µl) 
was measured by spectrophotometry wavelength of 670 nm. 
The H2S concentration of each sample was calculated from 
a calibration curve of 100-0.1 µg/ml NaHS. All reagents 
used were purchased from Sigma (Sigma Chemical Co., St. 
Louis, MO, USA). For the measurement of the plasma NO, 
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NO/ozone chemiluminescence technique was used. The ni-
trate concentration in plasma was measured using 5 µL of 
sample injected in a reaction vessel containing a reducing 
agent (0.8% of vanadium chloride in 1N of HCl to 95ºC) 
that converts the nitrate in NO, in equimolares amounts. 
The NO was dredged using helium gas, to the chamber 
of the chemiluminescence Sievers NO Analyzer (Sievers® 
Nitric Oxide Analyzer 280 (GE Analytical Instruments, 
Boulder, CO. USA).
Data were analyzed using the analysis of variance 
(ANOVA) - Correction Test - for repeated measures and 
Tukey test for multiple comparisons of means. The results 
were presented as means and standard errors from mean 
(SEM). Differences were considered statistically significant 
at p <0.05.
The study followed the aspects contained in Resolution 
466/12 and the research project was approved by Ethics 
Committee of the College of Medicine of Sao Jose do Rio 
Preto (FAMERP), with the approval number 189.871/12.
RESULTS
A total of 36 subjects with hypertension participated in 
the study, using antihypertensives for more than five years, 
and 16 participants were using antihypertensive drugs from 
the class of calcium channel antagonists and 20 partici-
pants were using antihypertensive drugs from the class of 
angiotensin-converting enzyme inhibitors, all participants 
underwent venous blood sample collection for analysis of 
plasma concentrations of nitrate and H2S.
Regarding the general characteristics of the group, 
69.4% of the patients were aged 60 years or more; 61.1% 
were female and 94.5% declared themselves white.
According to the figure below, the concentration of 
plasma NO was significantly higher in hypertensive patients 
that were taking angiotensin-converting enzyme inhibitors 
(p<0.03) when related to the concentration in hypertensive 
patients using calcium channel antagonists.
The H2S plasma concentration was significantly greater 
in hypertensive patients using calcium channel antagonists 
*Level of significance.
Figure 1 – NO plasma concentrations in hypertensive patients 
using calcium channel antagonists and inhibitors of angiotensin-
converting enzyme - Ribeirão Preto, SP, Feb. to Nov. 2013.
(p<0.002) when related to the concentration in hypertensive 
patients using angiotensin-converting enzyme inhibitors, as 
shown in the figure below.
 In figures 3 and 4 we observed that there was no sta-
tistically significant association between plasma concentra-
tions of nitrate and H2S in hypertensive individuals treated 
with calcium channel antagonists (p=0.09). We also did 
not observe statistically significant association between hy-
pertensive individuals treated with angiotensin-converting 
enzyme inhibitors (p=0.32).
** Level of significance.
Figure 2 – H2S plasma concentrations in hypertensive patients 
using calcium channel antagonists and inhibitors of angiotensin-
converting enzyme - Ribeirão Preto, SP, Feb. to Nov. 2013.
Figure 3 – Association between plasma nitrate and H2S concentra-
tions in hypertensive patients being treated with calcium chan-
nel antagonists (p=0.09) - Ribeirão Preto, SP, Feb. to Nov. 2013.
Figure 4 – Association between nitrate and H2S concentrations 
in plasma in hypertensive patients with drug therapy with angio-
tensin-converting enzyme inhibitors (p=0.32) - Ribeirão Preto, 
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DISCUSSION
One of the competencies of the nursing staff is the ad-
ministration of medicines. This brings up the need for a 
deep and up to date knowledge concerning pharmacology, 
so that practice is safe and based in scientific evidence. A 
study conducted with nurses in an intensive care unit had 
as objective to evaluate the knowledge of these professionals 
about drug interactions. The study demonstrated a relation-
ship of right and wrong answers of approximately 50% of 
nurses(8). Another study identified that nurses have insuf-
ficient knowledge in the practice of pharmacovigilance(9).
These findings demonstrate the need to implement ac-
tions to raise the knowledge of nursing professionals about 
Pharmacology, ensuring quality and safety in care. The 
present study contributes to the advancement in the un-
derstanding of mechanisms of action of antihypertensive 
drugs and about gaseous mediators involved in blood pres-
sure control, essential for clinical practice of the nurse.
A literature review carried out in Italy has recently 
pointed out that some antihypertensive drugs may im-
prove Endothelial dysfunction, particularly calcium chan-
nel antagonists (CCA) on microcirculation, angiotensin-
converting enzyme inhibitors (ACE Inhibitors) and AT-1 
receptors antagonists, mainly on arterial vessels(10). There is 
good evidence that Endothelial dysfunction is significantly 
associated with cardiovascular risk and can be considered 
as a barometer of the overall risk (the risk of risk factors)(11). 
Consequently, its prevention and treatment are essential in 
reducing cardiovascular complications.
In our research, hypertensive patients that were using 
angiotensin-converting enzyme inhibitors (ACE Inhibi-
tors) presented in larger NO plasma levels when compared 
to hypertensive patients using calcium channel antagonists. 
In a comparative study between angiotensin-converting en-
zyme inhibitors, calcium channel antagonists, beta blockers 
and diuretics on reactive hyperemia in patients with essen-
tial hypertension, found that the reactive hyperemia was 
significantly higher in the group treated with ACE Inhibi-
tors, and may be due to the Nitric oxide elevation(12).
Nitric oxide is among the most important vasodilat-
ing molecules, mostly in muscular arteries. It inhibits key 
events in the development of atherosclerosis, such as ad-
hesion and platelet aggregation, leukocyte adhesion and 
migration, proliferation of smooth muscle cells(13). Several 
studies are documenting that antihypertensive drugs medi-
cations contribute to the elevation of NO in plasma levels, 
such as Enalapril and Captopril (angiotensin-converting 
enzyme inhibitors)(14) and the Nisoldipina (calcium channel 
antagonist)(15).
Nitric oxide, carbon monoxide and hydrogen sulphide, 
belongs to gaseous transmitters that can be used therapeuti-
cally(16). The complex mechanism of raising AP in hyperten-
sion by the deficiency of NO involves accentuation of the 
sympathetic system tonus, and renin angiotensin system 
and oxidative stress(17-18).
Nitric oxide may spread from the endothelial cells to 
vascular smooth muscle cells and Guanylate Cyclase (GC) 
has been identified as an intracellular receptor of NO. Its 
activation leads to the release of the second messenger cyclic 
Guanosine monophosphate (cGMP) and to the activation 
of protein kinase (PK) G-dependent, resulting in decreased 
intracellular calcium concentration, followed by vasorelax-
ation. In addition, there are many other functions of the 
NO participating in the regulation of gene transcription, 
translation of mRNA and protein modification of several 
enzymes involved in mitochondrial respiration, mitogen-
esis and growth(19). The signaling system of Nitric Oxide 
(NO) - Guanosine monophosphate (cGMP) (NO-cGMP) 
is a well-featured modulator of cardiovascular function, in 
general, and blood pressure, in particular(20).
The renin-angiotensin-aldosterone system (RAAS) is 
also an important regulator of blood pressure and sodium-
water homeostasis. Multiple signalizing mechanisms reg-
ulate blood pressure. Both signaling and activity of NO-
cGMP, and RAAS play a central role in the homeostatic 
control of systemic arterial pressure(21). Previous studies have 
shown that Angiotensin II raises the vascular production 
of reactive oxygen species (ROS) and thus reduces the bio-
availability of NO and endothelium-dependent dilation(22). 
Impaired endothelium-dependent relaxation results from 
decreased bioavailability of NO, largely due to increased O2. 
This mechanism can be one of the explanations for raising 
of plasma levels in hypertensive patients using ACE Inhibi-
tors in our study.
ACE inhibitors also affect kinins receptors. The B1 
human receptor is directly activated by ACE Inhibitors 
for releasing NO most consistently in human endothelial 
cells(23), what can also explain the fact that the use of these 
drugs have in hypertensive plasma levels of the highest 
result found in this research. In addition, ACE Inhibitors 
therapy and low-calorie diet improve vasorelaxant response 
to acetylcholine(24).
Our study was the first to measure plasma concentra-
tions of H2S in hypertensive patients and showed that 
plasma levels of gaseous transmitter were higher in subjects 
using calcium channel antagonists when compared to the 
group of hypertensive patients using angiotensin-convert-
ing enzyme inhibitors.
Calcium channel antagonists reduce the calcium en-
try channels of voltage-dependent L-type of muscle cells, 
vascular dilating coronary arteries and others. In addition, 
some CCA activate the NO endothelial synthase or has an-
tioxidant properties, thereby increasing the bioavailability of 
NO. Particularly, dihydropyridine, can reverse the impaired 
endothelium-dependent vasodilation impaired in different 
places, including subcutaneous, epicardial, renal circulation 
and forearm. On forearm circulation, Nifedipine and Laci-
dipine can improve endothelial dysfunction, restoring the 
NO availability through a mechanism that is likely related 
to an antioxidant effect(25).
In the field of studies of H2S, Wilinski and colleagues 
at the Jagiellonian University in Poland have shown the 
greater impact of a variety of pharmacological agents on the 
production of endogenous H2S and postulated the drug-
modulatory role of H2S in this scenario(26). Drugs that alter 
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the channel sulfidation, mediated by H2S can be therapeutic 
agents and effective in the treatment of hypertension(27).
In addition to NO, H2S has also been identified re-
cently as a gaseous transmitter. By direct action on the KATP 
channels of smooth muscle cells, it has vasorelaxant proper-
ties. It has the potential to react with metal ions (Cu, Fe, 
Zn) in metalloprotein. The angiotensin-converting enzyme 
(ACE), responsible for vasoconstriction, is an enzyme that 
contains zinc. The H2S shows an inhibitory action on ACE 
activity in human surface endothelial cells, by interfering 
with zinc in the active center of this enzyme. So, next to the 
well-known influence of H2S in KATP channels in smooth 
muscle cells, the direct inhibitory effect on ACE can con-
tribute to the vasorelaxant effect of H2S in the vasculature, 
reducing the production of angiotensin II and inhibiting 
the degradation of bradykinin(28). The decrease of H2S un-
der hyperglycemic condition leads to an imbalance between 
oxidative and reductive species. The increase in oxidative 
species result in activation of the renin angiotensin system, 
which, in turn, contributes to the pathogenesis of renal 
dysfunction(29).
The H2S inhibits the activity of plasma renin and di-
minish angiotensin II production in plasma, thus generat-
ing preventive and therapeutic effects on renovascular hy-
pertension in rats(30). These data suggest that H2S plays an 
anti-hypertensive role not only for its action on the KATP 
channels of smooth muscle cells, but also to suppress the 
activity of the renin-angiotensin-aldosterone system. These 
findings may provide a therapeutic potential in the treat-
ment of renovascular hypertension, suppressing the exces-
sive activity of RAAS.
Our results suggest that CCA improve vascular func-
tion through raising plasma levels of H2S in hypertensive 
patients. This new mechanism, not related to its action on 
the KATP channels of smooth muscle cells and inhibition 
of ACE, may also explain the beneficial effects of CCA 
reported in the clinical literature.
We can cite as a limiting factor of the study the difficul-
ty of finding hypertensive patients using antihypertensive 
monotherapy, since the vast majority of medicinal require-
ments includes the combination of different antihyperten-
sive agents.
CONCLUSION
The findings of this research suggest that pharmaco-
therapy with ACE Inhibitors and CCA in hypertensive 
subjects can alter circulating concentrations of gaseous 
mediators, such as NO and H2S, noticing no association 
between these two mediators during treatments and these 
medications have as additional action mechanism the im-
provement of endothelial dysfunction by raising plasma 
levels of vasodilatory substances, which collaborates with 
their antihypertensive effects.
The research contributes to the advancement in knowl-
edge of ACE Inhibitors and CCA mechanisms of action 
and their relationship with plasma concentrations of gas-
eous mediators involved in the control of blood pressure. 
This information is relevant to the practice of nurses and 
their team, who cannot work in health institutions with the 
general knowledge of drugs based on empiricism. Thorough 
education of drug therapy should be part of nurses training 
and improvement for a reasoned and safe practice.
RESUMO
Objetivo: Avaliar o efeito do uso de anti-hipertensivos pertencentes às classes medicamentosas antagonistas de canais de cálcio e 
inibidores da enzima conversora de angiotensina nas concentrações plasmáticas de ácido sulfídrico e óxido nítrico em portadores de 
hipertensão arterial sistêmica. Método: Estudo transversal com abordagem quantitativa realizado com hipertensos em uso de anti-
hipertensivos das classes inibidores da enzima conversora de angiotensina ou antagonistas dos canais de cálcio. Resultados: Verificou-se 
que a concentração de óxido nítrico plasmático foi significativamente maior em hipertensos que estavam em uso de inibidores da enzima 
conversora de angiotensina (p<0.03) e que a concentração de ácido sulfídrico plasmático foi significativamente maior em hipertensos em 
uso de antagonistas dos canais de cálcio (p<0.002). Conclusão: Os achados sugerem que essas medicações possuem como mecanismo de 
ação adicional a melhora da disfunção endotelial por elevar os níveis plasmáticos de substâncias vasodilatadoras.
DESCRITORES
Hipertensão; Óxido Nítrico; Sulfeto de Hidrogênio; Anti-Hipertensivos.
RESUMEN
Objetivo: Evaluar el efecto del uso de antihipertensivos pertenecientes a las clases medicamentosas antagonistas de canales de calcio 
e inhibidores de la enzima convertidora de angiotensina en las concentraciones plasmáticas de ácido sulfhídrico y óxido nítrico en 
portadores de hipertensión arterial sistémica. Método: Estudio transversal con abordaje cuantitativo realizado con hipertensos que 
toman antihipertensivos de las clases de inhibidores de la enzima convertidora de angiotensina o antagonistas de los canales de calcio. 
Resultados: Se verificó que la concentración de óxido nítrico plasmático fue significativamente mayor en hipertensos que estaban 
usando inhibidores de la enzima convertidora de angiotensina (p<0.03) y que la concentración de ácido sulfhídrico plasmático fue 
significativamente mayor en hipertensos en uso de antagonistas de los canales de calcio (p<0.002). Conclusión: Los hallazgos sugieren 
que dichos fármacos tienen como mecanismo de acción adicional la mejora de la disfunción endotelial al elevar los niveles plasmáticos 
de sustancias vasodilatadoras.
DESCRIPTORES
Hipertensión; Óxido Nítrico; Sulfuro de Hidrógeno; Antihipertensivos
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